NKGen Biotech, Inc. (NKGN)
OTCMKTS · Delayed Price · Currency is USD
0.0021
0.00 (0.00%)
Aug 31, 2026, 9:52 AM EST
NKGen Biotech Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 0.01 | 0.11 | 0.03 | 0.12 | 0.35 |
Cash & Short-Term Investments | 0.01 | 0.11 | 0.03 | 0.12 | 0.35 |
Cash Growth | -82.35% | 307.69% | -77.78% | -66.67% | - |
Accounts Receivable | - | - | - | 0.03 | - |
Other Receivables | 0.02 | 0.02 | 0.03 | 0.07 | 0.07 |
Receivables | 0.02 | 0.02 | 0.03 | 0.1 | 0.07 |
Prepaid Expenses | 0.65 | 0.52 | 1.57 | 0.13 | 0.17 |
Restricted Cash | 0.02 | 0.13 | 0.25 | - | - |
Other Current Assets | 1.68 | 1.68 | 0.06 | 0 | 0.02 |
Total Current Assets | 2.38 | 2.46 | 1.93 | 0.35 | 0.61 |
Property, Plant & Equipment | 13.37 | 13.68 | 14.46 | 15.88 | 17.37 |
Other Intangible Assets | 0.1 | 0.1 | 0.09 | 0.1 | 0.09 |
Total Assets | 15.84 | 16.23 | 16.48 | 16.33 | 18.07 |
Liabilities
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 15.24 | 14.39 | 11.04 | 0.98 | 1.69 |
Accrued Expenses | 1.29 | 1.1 | 2.27 | 1.65 | 0.49 |
Short-Term Debt | 26.76 | 41.67 | 9.99 | 11.66 | 51.15 |
Current Portion of Leases | 0.15 | 0.15 | - | 0.38 | 0.46 |
Other Current Liabilities | 0.45 | 0.66 | 16.15 | 0.08 | 1.96 |
Total Current Liabilities | 43.89 | 57.97 | 39.45 | 14.74 | 55.74 |
Long-Term Debt | 11.08 | 10.84 | 9.93 | - | - |
Long-Term Leases | 0.21 | 0.25 | - | - | 0.36 |
Long-Term Deferred Tax Liabilities | 0.01 | 0.01 | 0.03 | 0.03 | 0.02 |
Other Long-Term Liabilities | 11 | 17.07 | 25.76 | - | - |
Total Liabilities | 66.17 | 86.14 | 75.17 | 14.77 | 56.12 |
Shareholders' Equity
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.01 | 0 | 0 | 0 | 0.01 |
Additional Paid-In Capital | 140.91 | 136.69 | 121.73 | 80.74 | 14.36 |
Retained Earnings | -191.07 | -206.42 | -162.13 | -79.18 | -52.42 |
Comprehensive Income & Other | -0.18 | -0.18 | -18.29 | - | - |
Shareholders' Equity | -50.33 | -69.91 | -58.69 | 1.56 | -38.05 |
Total Liabilities & Equity | 15.84 | 16.23 | 16.48 | 16.33 | 18.07 |
Additional Metrics
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 38.19 | 52.91 | 19.92 | 12.03 | 51.97 |
Net Cash (Debt) | -38.19 | -52.8 | -19.9 | -11.92 | -51.62 |
Net Cash Growth | - | - | - | - | - |
Net Cash Per Share | -1.10 | -1.83 | -1.29 | -1.87 | -3.62 |
Filing Date Shares Outstanding | 130.6 | 124.38 | 22.81 | 32.6 | 14.25 |
Total Common Shares Outstanding | 51.31 | 44.24 | 21.89 | 32.58 | 14.25 |
Working Capital | -41.51 | -55.51 | -37.52 | -14.39 | -55.13 |
Book Value Per Share | -0.98 | -1.58 | -2.68 | 0.05 | -2.67 |
Tangible Book Value | -50.43 | -70 | -58.79 | 1.47 | -38.14 |
Tangible Book Value Per Share | -0.98 | -1.58 | -2.69 | 0.05 | -2.68 |
Land | 5.03 | 5.03 | 5.03 | 5.03 | 5.03 |
Buildings | 8.33 | 8.33 | 8.33 | 8.33 | 8.31 |
Machinery | 4.8 | 4.8 | 4.88 | 4.81 | 4.71 |
Leasehold Improvements | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 |